Open AccessPercutaneous Estrogen Replacement Therapy
Author(s) -
Hoist J.,
Cajander S.,
Carlström K.,
Damber MG.,
Schoultz B.
Publication year - 1983
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348309155758
Subject(s) - estrone , medicine , estrogen , prolactin , transdermal , estrogen therapy , menopause , climacteric , endocrinology , percutaneous , gonadotropin , estriol , pharmacology , hormone
. A percutaneous gel containing 0.6 mg/g of estra‐diol‐17β was used for cyclic replacement therapy in 19 post‐menopausal women. Significantly increased serum concentrations of estradiol‐17β, unconjugated estrone, and total estrone were recorded during 6 months of treatment. In contrast to oral treatment the quotient of estrone/estradiol‐17β was maintained and even reduced during therapy. Significant gonadotropin inhibition was recorded and the es‐trogenic potency of 3 mg percutaneous estradiol‐17β was similar to that of oral estradiol‐17β 2 mg and 2.5 mg oral estrone sulphate. Prolactin levels remained constant during treatment. Therapy was effective in abolishing hot flushes in 17 out of the 19 women treated. The therapy was well accepted by the volunteers. Seventeen out of 19 women stated that the gel was easy to use in everyday life. Topic application may develop into an alternative treatment for climacteric complaints and may even have some metabolic advantages over oral treatment.